Welcome to our dedicated page for Immunome news (Ticker: IMNM), a resource for investors and traders seeking the latest updates and insights on Immunome stock.
Immunome, Inc. (IMNM) is a cutting-edge biotechnology firm specializing in the development of innovative cancer immunotherapies. Grounded in leveraging the human immune system, Immunome's unique approach involves utilizing the 'most highly educated' immune systems from patients who have successfully fought off their disease. This proprietary technology platform enables the simultaneous discovery of novel antigens and patient-derived, native antibodies that target those antigens.
The company employs a comprehensive suite of high-content screening technologies to identify specific and high-affinity antibodies that hold significant therapeutic potential. By harnessing these advanced techniques, Immunome aims to revolutionize cancer treatment and improve patient outcomes.
Immunome's primary pipeline includes promising preclinical and clinical assets, such as IM-1021 targeting fibroblast activation protein (FAP) and IM-4320, aimed at transforming the therapeutic landscape of oncology and infectious diseases, including COVID-19. The company is strategically positioned within the U.S. and focuses on establishing a broad spectrum of assets that can be efficiently developed through successive value inflection points.
The latest developments and achievements of Immunome reflect its commitment to innovation and excellence in the biopharmaceutical sector. The latest news showcases significant milestones, partnerships, and advancements in their research and development efforts, further solidifying their reputation as leaders in the field of antibody therapeutics.
Immunome (Nasdaq: IMNM), a biotechnology company developing first-in-class and best-in-class targeted cancer therapies, has announced its participation in two major investor conferences in March 2025.
The company will present at the TD Cowen 45th Annual Health Care Conference on March 4, 2025, at 1:10 p.m. ET. The conference runs from March 3-5, 2025.
Additionally, Immunome will participate in the Leerink Partners Global Healthcare Conference 2025 on March 10, 2025, at 1:40 p.m. ET. This conference is scheduled for March 10-12, 2025.
Live webcast links for both presentations will be available on the events tab of Immunome's investor website, with replay links accessible for 30 days following the live broadcasts.
Aro Biotherapeutics announced a leadership transition as co-founder Susan Dillon, Ph.D., steps down from her position as president and CEO to continue as chair of the Board of Directors. The company has appointed Purnanand Sarma, Ph.D. as the new CEO and board member, effective immediately.
Dr. Sarma brings over three decades of pharmaceutical experience and will lead the development of Aro's pipeline of siRNA-conjugate medications, including ABX1100, a novel Centyrin-GYS1 siRNA drug conjugate for Pompe disease treatment. His background includes extensive drug development experience and success in IPOs, M&A, and company transactions, most recently serving as CEO of Immunome.
The transition comes as Aro advances its mission to develop targeted short-interfering RNA (siRNA) medicines, with its lead program already in clinical testing. The company's focus remains on creating a new class of targeted siRNA medicines for intractable diseases using their proprietary Centyrin technology.
Immunome (NASDAQ: IMNM) announced that its Compensation Committee granted inducement awards to four new employees on February 3, 2025. The awards consist of non-statutory stock options to purchase a total of 51,000 shares of common stock under the Company's 2024 Inducement Plan.
The stock options have an exercise price of $10.32 per share, matching the Company's closing price on February 3, 2025. The options will vest over four years, with 25% vesting after one year and the remaining balance vesting monthly over the following 36 months, contingent on continued employment. These grants were approved as inducement material for employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Immunome (NASDAQ: IMNM) has successfully closed its upsized public offering, selling 22,258,064 shares of common stock at $7.75 per share, including the full exercise of underwriters' option to purchase an additional 2,903,225 shares. The offering generated gross proceeds of $172.5 million before deducting underwriting discounts, commissions, and expenses.
The offering was managed by multiple financial institutions, with J.P. Morgan, TD Cowen, Leerink Partners, and Guggenheim Securities acting as joint book-running managers, while Wedbush PacGrow served as lead manager. The offering was conducted under a shelf registration statement on Form S-3 filed with the SEC on February 13, 2024.
Immunome (Nasdaq: IMNM) has announced the pricing of an upsized public offering of 19,354,839 shares of common stock at $7.75 per share. The company expects to raise gross proceeds of $150.0 million before deducting underwriting discounts and expenses.
The offering includes a 30-day option for underwriters to purchase up to an additional 2,903,225 shares at the public offering price. The offering is expected to close on January 31, 2025. J.P. Morgan, TD Cowen, Leerink Partners, and Guggenheim Securities are acting as joint book-running managers, with Wedbush PacGrow as lead manager.
Immunome (NASDAQ: IMNM) has announced plans for an underwritten public offering of $125.0 million worth of common stock shares. The biotechnology company, focused on developing first-in-class and best-in-class targeted cancer therapies, will grant underwriters a 30-day option to purchase up to an additional 15% of the shares sold in the offering.
The offering will be managed by joint book-running managers J.P. Morgan, TD Cowen, Leerink Partners, and Guggenheim Securities, with Wedbush PacGrow acting as lead manager. The offering is being made through a shelf registration statement on Form S-3 filed with the SEC on February 13, 2024.
Immunome (NASDAQ: IMNM) announced key pipeline updates ahead of its presentation at the 43rd Annual J.P. Morgan Healthcare Conference. The company expects topline data from the Phase 3 RINGSIDE study of varegacestat, a daily oral gamma secretase inhibitor for desmoid tumors, in H2 2025.
The FDA has cleared the IND for IM-1021, a ROR1-targeted ADC, in Q4 2024. The company plans to submit an IND for IM-3050, a FAP-targeted radioligand therapy, by Q1 2025. Additionally, three novel ADC programs for solid tumors - IM-1617, IM-1340, and IM-1335 - are advancing in preclinical development.
Immunome (NASDAQ: IMNM) announced that its Compensation Committee granted inducement awards to four new employees on January 2, 2025. The awards consist of non-statutory stock options to purchase a total of 45,000 shares of common stock under the Company's 2024 Inducement Plan.
The stock options have an exercise price of $10.53 per share, matching the Company's closing price on January 2, 2025. The options will vest over four years, with 25% vesting after one year and the remaining balance vesting monthly over the following 36 months, contingent on continued employment. These grants were approved as inducement material for employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Immunome announced that its Compensation Committee granted inducement awards of non-statutory stock options to 15 new employees under the Company's 2024 Inducement Plan. The options allow purchase of 210,500 shares at $14.08 per share, based on the closing price on December 2, 2024. The options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over 36 months, contingent on continued employment.
Immunome (Nasdaq: IMNM), a biotechnology company specializing in targeted cancer therapies, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The company's management will engage in a fireside chat scheduled for Tuesday, December 3, 2024, at 4:30 p.m. Eastern time.
A live audio webcast will be accessible through the Investor Relations section of Immunome's website. Following the presentation, a replay will remain available for approximately 30 days.
FAQ
What is the current stock price of Immunome (IMNM)?
What is the market cap of Immunome (IMNM)?
What does Immunome, Inc. specialize in?
What is the core technology platform of Immunome?
What are the primary focus areas for Immunome?
Can you name some of Immunome's key pipeline assets?
Where is Immunome, Inc. based?
What is the goal of Immunome's development strategy?
How does Immunome identify high-affinity antibodies?
What distinguishes Immunome's approach to immunotherapy?
How does Immunome plan to impact cancer treatment?
What recent achievements has Immunome made?
